- Volume 16 Issue 3
DOI QR Code
Association of the PTEN IVS4 (rs3830675) Gene Polymorphism with Reduced Risk of Cancer: Evidence from a Meta-analysis
- Mandal, Raju K. (Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University) ;
- Akhter, Naseem (Department of Biosciences, Jamia Millia Islamia (A Central University)) ;
- Irshad, Mohammad (Department of Biosciences, Jamia Millia Islamia (A Central University)) ;
- Panda, Aditya K. (Department of Infectious Disease Biology, Institute of Life Sciences) ;
- Ali, Arif (Department of Biosciences, Jamia Millia Islamia (A Central University)) ;
- Haque, Shafiul (Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University)
- Published : 2015.03.04
PTEN (phosphatase and tensin homologue), as a tumor suppressor gene, plays a significant role in regulating cell growth, proliferation, and apoptosis. Results from published studies for association between the PTEN IVS4 I/D (rs3830675) polymorphism and cancer risk are inconsistent and inconclusive. We therefore conducted a meta-analysis to evaluate the potential association between PTEN IVS4 I/D polymorphism and risk of cancer in detail. We searched PubMed (Medline) and EMBASE web databases to cover all relevant studies published until December 2013. The meta-analysis was carried out and pooled odds ratios (ORs) and 95% confidence intervals (95%CIs) were used to appraise the strength of association. A total of 1,993 confirmed cancer cases and 3,200 controls were included from six eligible case-control studies. Results from overall pooled analysis suggested a significant effect of the PTEN IVS4 I/D polymorphism and cancer risk in all genetic models, i.e., allele (I vs D: OR=0.743, 95%CI=0.648 to 0.852, p=0.001), homozygous (II vs DD: OR=0.673, 95%CI=0.555 to 0.816, p=0.001), heterozygous (ID vs DD: OR=0.641, 95%CI=0.489 to 0.840, p=0.001), dominant (II+ID vs DD: OR=0.626, 95%CI=0.489 to 0.802, p=0.001) and recessive (II vs DD+ID: OR=0.749, 95%CI=0.631 to 0.889, p=0.001). Significant publication bias was detected during the analysis. The present meta-analysis suggests that the PTEN IVS4 I/D polymorphism is significantly associated with reduced risk of cancer. However, future larger studies with other groups of populations are warranted to clarify this association.
Supported by : Institute of Life Sciences, Central University
- Alimonti A, Carracedo A, Clohessy JG, et al (2010). Subtle variations in PTEN dose determine cancer susceptibility. Nat Genet, 42, 454-8. https://doi.org/10.1038/ng.556
- Besson A, Robbins SM, Yong VW (1999). PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem, 263, 605-11. https://doi.org/10.1046/j.1432-1327.1999.00542.x
- Canbay E, Kahraman OT, Bugra D, et al (2013a). Association between PTEN IVS4 polymorphism and development of colorectal cancer in a Turkish population. Expert Opin Ther Targets, 17, 1-6. https://doi.org/10.1517/14728222.2013.727398
- Canbay E, Kahraman OT, Bugra D, et al (2013b). Increased gastric cancer risk with PTEN IVS4 polymorphism in a Turkish population. Genet Test Mol Biomarkers, 17, 249-53. https://doi.org/10.1089/gtmb.2012.0306
- Carroll BT, Couch FJ, Rebbeck TR, et al (2000). Polymorphisms in PTEN in breast cancer families. J Med Genet, 36, 94-96.
- Cheng T, Zhang J, Cheng Y, et al (2012). Relationship between PTEN and livin expression and malignancy of renal cell carcinomas. Asian Pac J Cancer Prev, 13, 2681-5 https://doi.org/10.7314/APJCP.2012.13.6.2681
- Cohn LD, Becker BJ (2003). How meta-analysis increases statistical power. Psychol Methods, 3, 243-53.
- DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-188. https://doi.org/10.1016/0197-2456(86)90046-2
- Duval S, Tweedie R (2000). Trim and ﬁll: a simple funnelplotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63. https://doi.org/10.1111/j.0006-341X.2000.00455.x
- Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 7109, 629-34.
- Ge H, Cao YY, Chen LQ, et al (2008). PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis Esophagus, 21, 409-15. https://doi.org/10.1111/j.1442-2050.2007.00786.x
- George DJ, Shepard TF, Ma J, et al (2001). PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 10, 411-412.
- Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 7414, 557-60.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jia-Li X, Zhen-Wu W, Ling-Min H, et al (2012). Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinumbased chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev, 13, 2157-62. https://doi.org/10.7314/APJCP.2012.13.5.2157
- Li DM, Sun H (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res, 57, 2124-9.
- Li J, Yen C, Liaw D, Podsypanina K, et al (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-1947. https://doi.org/10.1126/science.275.5308.1943
- Lichtenstein P, Holm NV, Verkasalo PK, et al (2000). Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85. https://doi.org/10.1056/NEJM200007133430201
- Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary Genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9 https://doi.org/10.7314/APJCP.2013.14.6.3403
- Mandal RK, Yadav SS, Panda AK (2013). Meta-analysis on the association of nucleotide excision repair gene XPD A751C variant and cancer susceptibility among Indian population. Mol Biol Rep, 41, 713-9.
- Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 4, 719-48.
- Munafo MR, Flint J (2004). Meta-analysis of genetic association studies. Trends Genet, 20, 439-444. https://doi.org/10.1016/j.tig.2004.06.014
- Onay VU, Briollais L, Knight JA, et al (2006). SNP-SNP interactions in breast cancer susceptibility. BMC Cancer, 6, 114. https://doi.org/10.1186/1471-2407-6-114
- Ozturk O, Canbay E, Kahraman OT, et al (2013). HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer. Mol Biol Rep, 40, 1813-8. https://doi.org/10.1007/s11033-012-2235-2
- Pandurangan AK (2013). Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev, 14, 2201-5 https://doi.org/10.7314/APJCP.2013.14.4.2201
- Pharoah PD, Dunning AM, Ponder BA, et al (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60. https://doi.org/10.1038/nrc1476
- Salmena L, Carracedo A, Pandolfi PP (2008). Tenets of PTEN tumor suppression. Cell, 133, 403-14. https://doi.org/10.1016/j.cell.2008.04.013
- Steck PA, Pershouse MA, Jasser SA, et al (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15, 356-62. https://doi.org/10.1038/ng0497-356
- Sun H, Lesche R, Li DM, et al (1999). PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA, 96, 61996204.
- Tamura M, Gu J, Matsumoto K, et al (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280, 1614-7. https://doi.org/10.1126/science.280.5369.1614
- Tamura M, Gu J, Takino T, et al (1999). Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res, 59, 442-9.
- Wen-Ting X, Zhen Yang, Nong-Hua Lu (2014) Roles of PTEN (phosphatase and tensin homolog) in gastric cancer development and progression. Asian Pac J Cancer Prev, 15, 17-24. https://doi.org/10.7314/APJCP.2014.15.1.17
- Woolf B (1955). On estimating the relation between blood group and disease. Ann Hum Genet, 19, 251-3. https://doi.org/10.1111/j.1469-1809.1955.tb01348.x
- Wu R, Li B (1999). A multiplicative-epistatic model for analyzing interspecific differences in outcrossing species. Biometrics, 2, 355-65.
- Wu X, Senechal K, Neshat MS, et al (1998). The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA, 95, 15587-91. https://doi.org/10.1073/pnas.95.26.15587
- Zhou YH, Tan F, Hess KR, et al (2003). The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res, 9, 3369-75.